Publications by authors named "M Schiappoli"
Article Synopsis
- Hypereosinophilic syndromes (HES) are rare immune conditions marked by high levels of eosinophils in the blood, with the idiopathic subtype (I-HES) being particularly hard to diagnose due to varied symptoms and overlap with other diseases.
- Diagnosing HES is complicated by the lack of specific tests, the need for referrals to various specialists, and the absence of a standard treatment approach, highlighting the need for better clinician awareness.
- The review emphasizes the importance of increasing understanding among healthcare providers and proposes a new multidisciplinary model to improve patient care and address the challenges faced in managing HES.
Background: Increasing evidence is available about the presence of increased serum concentration of immunoglobulin (Ig) free light chains (FLCs) in both atopic and non-atopic inflammatory diseases, including severe asthma, providing a possible new biomarker of disease.
Methods: We analyzed clinical and laboratory data, including FLCs, obtained from a cohort of 79 asthmatic subjects, clinically classified into different GINA steps. A control group of 40 age-matched healthy donors (HD) was considered.
Adherence to treatment is essential in chronic rhinosinusitis with nasal polyposis (CRSwNP). Intranasal corticosteroids (INCS) are the first-line therapy, followed by systemic corticosteroids and surgery if needed. In cases of refractory disease, biologics are added to conventional treatment, making adherence to INCS crucial in assessing eligibility for these targeted therapies.
View Article and Find Full Text PDFDupilumab is currently approved for the treatment of Type 2 severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Few studies have specifically reported on dupilumab efficacy on asthma outcomes as a primary objective in a real-life setting, in patients with and without CRSwNP. Our study aimed to explore the efficacy of dupilumab on functional, inflammatory, and patient-reported outcomes in asthma patients across different disease phenotypes and severity, including mild-to-moderate asthma coexisting with CRSwNP.
View Article and Find Full Text PDFIntroduction: Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, effectively blocks both IL-4 and IL-13 mediated pathways. Its introduction has represented a significant advancement in the treatment of severe asthma and other Type 2 (T2) conditions, including nasal polyps, atopic dermatitis, and eosinophilic esophagitis. To date, Dupilumab has demonstrated optimal efficacy and safety profile.
View Article and Find Full Text PDF